Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GAIT

This article was originally published in The Tan Sheet

Executive Summary

Glucosamine/Chondroitin Arthritis Intervention Trial has begun patient recruitment, NIH announces Dec. 11. The $14 mil. study, co-sponsored by NCCAM and the National Institute of Arthritis & Musculoskeletal & Skin Diseases, has expanded over last eight months to a 24-week, placebo-controlled, parallel, double-blind, five-arm clinical trial assessing efficacy of supplements in treating knee pain of osteoarthritis. An additional $3.4 mil. "sub-study" jointly funded by NCCAM and NIAMS has been added to primary trial to evaluate whether ingredients impact progression of knee OA. Half of patients enrolled in initial trial will receive blinded treatment for an additional 18 months, and knee radiographs obtained at onset of treatment and after one and two years will be compared and evaluated for any structural change

You may also be interested in...



Chondroitin/Glucosamine Osteoarthritis Risk Reduction Claim Requested

Weider Nutrition International seeks FDA approval for claims that products containing glucosamine and/or chondroitin sulfate "may reduce the risk of osteoarthritis," according to a health claim petition filed by the firm

Chondroitin/Glucosamine Osteoarthritis Risk Reduction Claim Requested

Weider Nutrition International seeks FDA approval for claims that products containing glucosamine and/or chondroitin sulfate "may reduce the risk of osteoarthritis," according to a health claim petition filed by the firm

Chondroitin/Glucosamine Osteoarthritis Risk Reduction Claim Requested

Weider Nutrition International seeks FDA approval for claims that products containing glucosamine and/or chondroitin sulfate "may reduce the risk of osteoarthritis," according to a health claim petition filed by the firm

Related Content

Topics

UsernamePublicRestriction

Register

PS092006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel